Aceclofenac/diacerein/glucosamine - Jenburkt Pharmaceuticals

Drug Profile

Aceclofenac/diacerein/glucosamine - Jenburkt Pharmaceuticals

Alternative Names: Diacerein/aceclofenac/glucosamine; Glucosamine/aceclofenac/diacerein

Latest Information Update: 19 Feb 2016

Price : $50

At a glance

  • Originator Jenburkt Pharmaceuticals
  • Class Analgesics; Anthraquinones; Anti-inflammatories; Antirheumatics; Carbohydrates; Disease-modifying antirheumatics; Esters; Hexosamines; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Peripheral nervous system agents; Phenylacetates; Sensory system agents; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Interleukin 1 receptor antagonists; Nitric oxide synthase type II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Osteoarthritis

Most Recent Events

  • 19 Feb 2016 No development reported - Phase-III for Osteoarthritis in India (PO)
  • 05 Feb 2013 Jenburkt Pharmaceuticals completes a phase III trial in Osteoarthritis in India (CTRI2010-091-001092)
  • 15 Jul 2010 Phase-III clinical trials in Osteoarthritis in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top